Venter W F, Kaiser B, Pillay Y, Conradie F, Gomez G B, Clayden P, Matsolo M, Amole C, Rutter L, Abdullah F, Abrams E J, Casas C P, Barnhart M, Pillay A, Pozniak A, Hill A, Fairlie L, Boffito M, Moorhouse M, Chersich M, Serenata C, Quevedo J, Loots G
Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
S Afr Med J. 2016 Dec 21;107(1):28-30. doi: 10.7196/SAMJ.2016.v107.i1.12058.
Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.
抗逆转录病毒药物是艾滋病项目的一项重大成本驱动因素。目前的一线治疗方案在实际项目中表现良好，但对病毒学耐药性的屏障较低，且仍具有限制依从性的毒性。新药研发可能意味着我们能够获得更安全、更有效且更便宜的治疗方案，但前提是要开展适当的临床试验。我们简要讨论了这些试验，并证明如果试验成功，南非艾滋病项目将节省大量成本。
